Project Grant R43CA295247
Award Date
9/1/24
Completion Date
8/31/25
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Utah, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $601,364 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Data Driven Bioscience Inc. for the project "Clinical Validation of DuoSeq, a Swiss Army Knife Genomic Approach to Diagnosis of Blood Cancers." The funding supports the analytical and clinical validation of extended applications for the DuoSeq assay, a novel approach that enables simultaneous DNA and RNA sequencing from a single workflow to...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...
The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $646,186 Project Grant to Nord Bio Inc. in Wilmington, Delaware. The grant aims to develop and evaluate a non-invasive assay to detect and monitor circulating tumor DNA (ctDNA) levels in saliva samples for patients with head and neck squamous cell carcinoma (HNSCC). The project will leverage duplex sequencing, genomic analysis algorithms, and DNA methylation data to enhance the...
The National Cancer Institute (NCI) awarded a $734,980 Project Grant under the Cancer Biology Research (CFDA 93.396) federal grant program to Aperture Bio, Inc., a woman-owned small business located in Boston, MA. The goal of this 1-year project is to commercialize a platform for rapid, single-cell proteomic profiling to enable improved diagnostic and treatment outcomes for cancer patients. The funded work aims to develop a validated panel for profiling immune cells, which can be used on...
The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Exai Bio Inc., a small disadvantaged business located in Palo Alto, California. The grant will fund the development of a novel liquid biopsy assay and artificial intelligence (AI) model for early detection of non-small cell lung cancer (NSCLC) and prediction of NSCLC subtypes. The project aims to validate the performance of this new assay for detection of minimal...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop an innovative circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of immunotherapy treatments in non-small cell lung cancer patients. The $990,771 award to Binary Genomics, Inc. over the 2-year project period from 09/2024 to 08/2026 will support advancing the company's epigenetic-based ctDNA detection approach...
The National Cancer Institute (NCI) awarded a $398,738 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Pre-Cancer Diagnosis, LLC to develop a highly sensitive DNA hypermethylation-based diagnostic kit to identify Barrett's Esophagus (BE) patients at high risk of progressing to esophageal adenocarcinoma (EAC). The key objectives are to: 1) validate the hypermethylation genes and develop a methylation diagnostic kit to differentiate high-risk BE patients...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $399,491 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Northridge Tri-Modality Imaging Inc. The grant will fund the upgrade of the company's gantry-based combined X-ray CT and fluorescent tomography (FLT) imaging system to add bioluminescence tomography (BLT) capability. This will enable the system to acquire co-registered 3D X-ray CT, FLT, and BLT images...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program for Cancer Detection and Diagnosis Research (CFDA 93.394), provides $554,653 to the Institute for Systems Biology (ISB) to develop and validate the "RareCyteFinder" toolkit. This label-free, genome-wide analysis platform aims to enable unbiased identification and comprehensive molecular profiling of rare disseminated tumor cells, including circulating tumor cells (CTCs) and isolated tumor...